

- pathophysiology of, 2620–2621
 primary, 2620
 secondary, 2620
 tardive, 2624
 treatment of, 2621
 in Wilson's disease, 2519
- Dystonia plus syndromes, 2620
 Dystonic storm, 2621
 Dystroglycans, 462e-8, 462e-8f, 462e-9f
 Dystrophia myotonica. *See* Myotonic dystrophy
 Dystrophic calcification, 363, 426e-7t, 426e-8
 Dystrophin, 436, 462e-6, 462e-8, 462e-8f, 462e-9f, 1556f
- Dysuria, **60e-1**
DYT gene mutations, 2620
- E**
- EAEC (enteroaggregative *E. coli*), 1028t, 1031
 EAP (extracellular adherence protein), 956
 Ear. *See also* Hearing loss
 anatomy and physiology of, 217, 218f
 chondritis of, 2203, 2204f
 infections of
 auricular cellulitis, 228
 vs. auricular chondritis, 2204
 otitis externa, 228–229, 1045t, 1046–1047, 1348
 otitis media. *See* Otitis media
P. aeruginosa, 1046–1047
 perichondritis, 228
- Early after depolarizations (EADs), 273e-3–4, 273e-3f
 Early repolarization syndrome, 1498
 Eastern Cooperative Oncology Group (ECOG) fatigue assessment, 63
 performance scale, 103e-7, 472, 472t
 Eastern equine encephalitis virus, 1306t, 1316
- Eating disorders
 anorexia nervosa, 259, **2719**
 avoidant/restrictive food intake disorder, 2719
 binge-eating disorder, **2720**
 bulimia nervosa. *See* Bulimia nervosa
 constipation in, 273–274
 diarrhea in, 270
 hypokalemia in, 307
 sleep-related, 192
- Eaton-Lambert syndrome. *See* Lambert-Eaton myasthenic syndrome (LEMS)
- Ebola virus, 261e-8, 1324, 1324f
 Ebola virus disease
 clinical features of, 783, 1327–1328, 1327t
 complications of, 1328
 control and prevention of, 1328–1329
 diagnosis of, 1328
 epidemiology of, 782–783, 1324, 1325f, 1326f
 pathogenesis of, 1326–1327
 prognosis of, 1328
 treatment of, 1328
- Ebstein's anomaly, 1527
 Eburnation, 1443
 EBV. *See* Epstein-Barr virus (EBV)
 EBV infections. *See* Epstein-Barr virus (EBV) infections
- E-cadherin, in gastric cancer, 534
 Ecallantide, 2120
 Ecamsule, 391, 391t
 Ecchymoses, 127, 403, 721, 721f, 1442
 ECF-A (eosinophil chemotactic factor of anaphylaxis), 372e-15t, 422
- ECG. *See* Electrocardiography (ECG)
 Echinocandins, 1331, 1344t, 1352t, 1353, 1910
 Echinococcosis (hydatid disease)
 clinical features of, 152e-4t, 1432–1433, 1561
 diagnosis of, 245e-2t, 245e-6t, 1433
 eosinophilia in, 245e-6t
 epidemiology of, 152e-4t, 1432
 etiology of, 245e-2t, 1432
 incubation period for, 152e-4t
 joint involvement in, 837
 prevention of, 152e-4t, 1434
 in returning war veterans, 152e-4t
 staging of, 1433, 1433f
 treatment of, 152e-4t, 1433–1434
- Echinococcus granulosus*, 245e-2t, 1432. *See also* Echinococcosis (hydatid disease)
Echinococcus multilocularis, 245e-2t, 1432. *See also* Echinococcosis (hydatid disease)
- Echinocytes, 81e-1
 Echocardiography, **270e-1**
 after myocardial infarction, 270e-19–20, 270e-20f
 in aortic dissection, 1641
 in atrial septal defect, 270e-25, 270e-25f, 297e-7f, 297e-8f, 1521, 1522f
 in cardiac amyloidosis, 271e-6f, 271e-6v
 in cardiac tumors, 270e-23–24, 270e-24f, 289e-1, 289e-1f
 in chest pain evaluation, 102, 271e-1f, 271e-1v
 contrast agents in, 270e-9
 in cor pulmonale, 1506
 Doppler, 270e-1–2, 270e-2f
 hand-held equipment for, 270e-2, 270e-3f
 in heart murmurs, 51e-8, 1440
 in hypertrophic cardiomyopathy, 271e-6f, 271e-6v
 in infective endocarditis, 270e-24, 270e-24f, 820, 820f, 821f
 in multiple/mixed valvular heart disease, 1552
 in myocardial function assessment, 265e-9
 in myocardial infarction, 271e-1f, 271e-1v, 1601
 in pericardial effusion, 270e-22–23, 270e-22f, 271e-8f, 271e-8v, 1572f
 principles of, 270e-1–2, 270e-1f
 in pulmonary embolism evaluation, 1634
 in pulmonary hypertension, 271e-9f, 271e-9v, 1655–1656, 1657f
 in pulsus paradoxus, 271e-8f, 271e-8v
 in rheumatic heart disease, 2151f, 2151t, 2154v
- stress
 advantages of, 270e-10
 in CAD evaluation, 270e-10, 270e-26v, 271e-1f, 271e-1v
 indications for, 270e-2
 in ischemic heart disease evaluation, 1585
 for risk stratification, 270e-14, 270e-14f
 three-dimensional, 270e-1, 270e-2f
 transesophageal. *See* Transesophageal echocardiography
- two-dimensional, 270e-1, 270e-1f
 in valvular heart disease, 270e-15–16
 aortic regurgitation, 270e-17–18, 270e-17f, 1536
 aortic stenosis, 270e-16–17, 270e-17f, 271e-5f, 271e-5v, 297e-6f, 1531
 mitral regurgitation, 270e-18–19, 270e-18f, 270e-19f, 1545, 2154v
 mitral stenosis, 270e-19, 270e-19f, 1540, 2154v
 mitral valve prolapse, 270e-16, 1546–1547
 tricuspid regurgitation, 1548
 tricuspid stenosis, 1548
 in ventricular septal defect, 270e-25
- Echolalia, 177t, 178, 2623
 Echo-planar magnetic resonance imaging, 440e-8
- Echoviruses, 1289
 Echovirus infections
 chronic meningitis, 908t
 rash in, 128t, 135, 362, 362t, 1292
- Eclampsia, 49, 1626t
 ECMO. *See* Extracorporeal membrane oxygenation (ECMO)
- ECOG. *See* Eastern Cooperative Oncology Group
- Econazole, 233
 Economic issues
 health and, 9
 in medical care, **15e-1**, 21
 clinical decision-making and, 15e-2–3, 21
 health insurance and use of services, 15e-2–3
 pricing structures, 15e-3
 selection, 15e-1–2
 in population aging, 93e-4
- Ecstasy (MDMA), 168, 301, 469e-3
- Ectasias, vascular. *See* Vascular ectasias
 Ecthyma, 349
 Ecthyma gangrenosum
 in burn patient, 166e-2
 in cancer patient, 486
 clinical features of, 76e-12f, 132t, 135, 1044
 epidemiology of, 132t, 135
 etiology of, 132t, 183e-2, 782, 830, 1044
 in sepsis/septic shock, 1754
 skin manifestations of, 25e-9f, 132t, 369, 782
- Ectopia lentis, 436e-6f
 Ectopic ossification, 426e-7t, 426e-8
 Ectopic pregnancy, 106t, 338
 Ectopy, cervical, 876
 Ectropion, 199, 1977
 Eculizumab
 for familial hemolytic-uremic syndrome, 657, 1864
 for kidney transplant rejection, 1829
 for membranoproliferative glomerulonephritis, 1841
 for paroxysmal nocturnal hemoglobinuria, 661–662, 661f
- Eczema, **344**. *See also* Atopic dermatitis
 asteatotic, 342f, 346
 clinical features of, 344
 dyshidrotic, 76e-2f, 341t, 342f, 346, 346f
 hand, 342f, 346, 346f
 nummular, 346
- Eczema herpeticum, 1178
 ED. *See* Erectile dysfunction (ED)
 EDD (extended daily dialysis), 1811
 Edema, **250**
 approach to the patient, 253
 brain, 1777
 in cardiovascular disease, 1439
 in cirrhosis, 252, 252t
 clinical features of, 251
 cytotoxic, 1777
 distribution of, 253
 drug-induced, 252, 253t
 etiology of, 251–253, 252t, 253t
 in heart failure, 251–252, 252t, 1504
 heat-related, 479e-1
 hypoalbuminemia and, 294
 inflammatory, 250
 in kidney disease, 252, 252t
 localized, 253
 localized hypoxia and, 248
 lower extremity, 1443
 in nephrotic syndrome, 252, 252t
 of nutritional origin, 252–253
 pathogenesis of, 250–251, 251f, 332e-10f
 pitting, 251, 1443
 in pneumonia, 804
 pulmonary. *See* Pulmonary edema
 refeeding, 253
 stasis dermatitis and, 346
 vasogenic, 1777
- Edentulousness, 242
 Edinger-Westphal nuclei, 195
 Edoxaban, 756–757, 756t, 1635, 2570
 Edrophonium
 for anticholinesterase testing
 in botulism, 989
 false-positive results from, 2702
 in myasthenia gravis, 208, 2702, 2702t
 in snakebite, 2737t
 for snakebite treatment, 2737, 2737t
- EDSS (Expanded Disability Status Score), 2668t
 EDTA (ethylenediaminetetraacetic acid), 2237
Edwardsiella tarda infections, 1025, 1035–1036
 EEG. *See* Electroencephalography (EEG)
 Efalizumab, 372e-31
 Efavirenz
 adverse effects of, 1274t, 1278
 contraindications to, 1273
 for HIV infection, 1274t, 1278
 metabolism of, 34t
 molecular structure of, 1276f
 resistance to, 773, 1278, 1279f
- Eflornithine
 action of, 246e-8
 adverse effects of, 246e-3t